Success Metrics

Active Trials
10(91%)

Phase Distribution

Ph phase_3
4
36%
Ph phase_1
7
64%

Phase Distribution

7

Early Stage

0

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
7(63.6%)
Phase 3Large-scale testing
4(36.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

10

trials recruiting

Total Trials

11

all time

Status Distribution
Active(11)

Detailed Status

Recruiting6
Active, not recruiting4
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
10
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 17 (63.6%)
Phase 34 (36.4%)

Trials by Status

recruiting655%
not_yet_recruiting19%
active_not_recruiting436%

Recent Activity

10 active trials
Showing 5 of 11
recruitingphase_1

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

NCT07407933
active_not_recruitingphase_3

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)

NCT06629597
active_not_recruitingphase_3

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)

NCT06612151
recruitingphase_3

A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer

NCT07739758
recruitingphase_3

A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy

NCT07487896
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07407933Phase 1

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Recruiting
NCT06629597Phase 3

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma (TAISHAN-301)

Active Not Recruiting
NCT06612151Phase 3

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)

Active Not Recruiting
NCT07739758Phase 3

A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer

Recruiting
NCT07487896Phase 3

A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy

Recruiting
NCT06394414Phase 1

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

Active Not Recruiting
NCT05434234Phase 1

A Study of YL201 in Patients With Advanced Solid Tumors

Recruiting
NCT07208773Phase 1

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Recruiting
NCT06898957Phase 1

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Active Not Recruiting
NCT07307053Phase 1

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Not Yet Recruiting
NCT07258979Phase 1

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Recruiting

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11